Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06382155 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature
A Phase 2 study of Idiopathic Short Stature, sponsored by BioMarin Pharmaceutical.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 20
- Study locations
NCT06382155 is a Phase 2 study of Idiopathic Short Stature that is actively recruiting participants, run by BioMarin Pharmaceutical. The registered enrollment target is 100 participants, below the 163-participant average among 4 other Idiopathic Short Stature trials with a reported enrollment target (39% lower). The trial reports 20 study locations across 8 states.
The verdict
NCT06382155, a Phase 2 study of Idiopathic Short Stature, is actively recruiting participants, sponsored by BioMarin Pharmaceutical.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate i) the effect of multiple doses of vosoritide and ii) the effect of the therapeutic dose of vosoritide compared to human growth hormone (hGH)(hGH; only in the United States), in children with idiopathic short stature (ISS).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Vosoritide Injection
- DRUG Human Growth Hormone
Study Locations (20)
California
- Consano Clinical Research, LLC - California City
- Rady Children's Hospital - San Diego - California City
- Children's Hospital of Orange County Main Campus - Orange - California City
- Children's Hospital Los Angeles - Los Angeles
- Children's Hospital Oakland Research Institute - Oakland
- Center Of Excellence in Diabetes and Endocrinology - Sacramento
- Lundquist Institute for Biomedical Innovation (LA BioMed) - Torrance
Florida
- Nemours Children's Specialty Care Jacksonville - Jacksonville
- Nicklaus Children's Hospital - Miami
- Optimal Research Sites - Orange City
- Nemours Children's Health System - Corporate Headquarters - Pensacola
Idaho
- St. Luke's Children's Endocrinology - Boise
- Rocky Mountain Clinical Research - Idaho Falls - Idaho Falls
Kentucky
- Kentucky Children's Hospital - Lexington
- University of Louisville School of Medicine - Louisville
Louisiana
- Velocity Clinical Research - MedPharmics - Lafayette - Lafayette
- Ochsner Health Center for Children - New Orleans - New Orleans
District of Columbia
- The Children's National Research Institute - Washington D.C.
Georgia
- Centricity Research - Columbus
Iowa
- University of Iowa Stead Family Children's Hospital - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2024-10-21 |
| Est. Completion | 2036-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06382155
The ClinicalTrials.gov registry entry for NCT06382155 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 163-participant average among 4 other Idiopathic Short Stature trials with a reported enrollment target (39% lower). The listed sponsor is BioMarin Pharmaceutical, which has 80 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Idiopathic Short Stature appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06382155 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Idaho.
Frequently Asked Questions
What is clinical trial NCT06382155 about?
NCT06382155 is a clinical study titled "A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature". The purpose of this study is to evaluate i) the effect of multiple doses of vosoritide and ii) the effect of the therapeutic dose of vosoritide compared to human growth hormone (hGH)(hGH; only in the United States), in children with idiopathic short stature (ISS).
What is the current status of trial NCT06382155?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2024-10-21. Estimated completion is 2036-12.
What conditions does trial NCT06382155 study?
This clinical trial studies the following conditions: Idiopathic Short Stature.
What interventions are being tested in trial NCT06382155?
The interventions under investigation include: Placebo (DRUG), Vosoritide Injection (DRUG), Human Growth Hormone (DRUG).
Who is sponsoring clinical trial NCT06382155?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06382155 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Short Stature
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Growth in Children With Idiopathic Short Stature
RECRUITING
-
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
RECRUITING · Phase 3
-
Genotropin Study Assessing Use of Injection Pen
COMPLETED · Phase 3
-
Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.